Stockreport

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium, Inc.  (EQ) 
Last equillium, inc. earnings: 3/26 04:07 pm Check Earnings Report
PDF EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseasesEQ504 has a unique, multi-modal, n [Read more]